Results from an interventional trial evaluating rosuvastatin (JUPITER)25 suggest that CRP may assist in risk stratifying healthy participants without hyperlipidemia for rosuvastatin treatment in primary prevention of atherosclerosis. This evidence concerns the gene CRP and hyperlipidemia.